Alterity Therapeutics Ltd: Phase 2 DMC Recommends Continuing Clinical Trial as Planned
Alterity Therapeutics Ltd: Ceasing to be a substantial holder
Alterity Therapeutics Ltd: Change in substantial holding
Alterity Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Alterity Therapeutics Ltd: Application for quotation of securities - ATH
Alterity Therapeutics Ltd: Alterity Presents New Data on ATH434
Alterity Therapeutics Ltd: Change in substantial holding
Alterity Therapeutics Ltd: Alterity Parkinson's and MSA Data Featured at AAN Meeting
Alterity Therapeutics Ltd: Application for quotation of securities - ATH
Alterity Therapeutics Ltd: Options Prospectus
Alterity Therapeutics Ltd: Results of Extraordinary General Meeting
Alterity Therapeutics Ltd: Alterity to Present New ATH434 Data at Orphan Drug Congress
Alterity Therapeutics Ltd: Alterity Receives a $3.9 million R&D Tax Incentive Refund
Alterity Therapeutics Ltd: Change in substantial holding
Alterity Therapeutics Ltd: Notice of Extraordinary General Meeting/Proxy Form
Alterity Therapeutics Ltd: Becoming a substantial holder
Alterity Therapeutics Ltd: Change in substantial holding
Alterity Therapeutics Ltd: Notice Under Section 708A
Alterity Therapeutics Ltd: Application for quotation of securities - ATH
Alterity Therapeutics Ltd: Change in substantial holding
No Data